Advice

following an abbreviated submission:

etrasimod (Velsipity®) is accepted for use within NHSScotland.

Indication under review: for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Etrasimod offers an additional treatment choice in the therapeutic class of sphingosine 1-phosphate (S1P) receptor modulators.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

Download detailed advice267KB (PDF)

Download

Medicine details

Medicine name:
etrasimod (Velsipity
SMC ID:
SMC2655
Indication:

For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Pharmaceutical company
Pfizer Ltd
BNF chapter
Gastro-intestinal system
Submission type
Abbreviated
Status
Accepted
Date advice published
10 June 2024